



Stargardt Makula Distrofili Pediatrik bir olguda MKH uygulaması

PROF DR AYŞE ÖNER, FEBO, PHD
ACIBADEM SAĞLIK GRUBU
ATAKENT/KAYSERİ HASTANELERİ






- ▶ A.İ.G, 11 yaş kız çocuđu
- ▶ Rutin kontrolde sađ gözünün az gördüđü saptanmıř
- ▶ Testler sonucu Stargardt'ın Makula Distrofisi (SMD) tanısı konmuř.
- ▶ ABCA4 gen mutasyonu (+)
- ▶ Ebeveynler sađlık sektöründe
- ▶ Tüm tedavi seęeneklerini arařtırıp kök hücre uygulaması için bařvurdular.

İlk Muayene (04.11.2019)

- ▶ GK: 0.05/0.8 Snellen
- ▶ Sikloplejili Otoref: -0.25/-0.50
- ▶ Ön segment normal
- ▶ Fundus: Her iki makulada pigment deęişiklikleri ve ince flekler (Saę belirgin)







Flaş ERG



Mf ERG

SAĞ





SOL

- ▶ Etik onay (Pediatrik olgular için alınmış idi. 2019-ERÜ)
- ▶ Sağlık Bakanlığı Organ Doku ve Kök Hücre Nakli Kurulu'ndan hasta adına 'Klinik deneme tedavisi' kapsamında onay alındı.

04.03.2020 Sağ göze suprakoroidal MKH uygulaması (İlk başvurudan 4 ay sonra)

Pre op GK: 0.05/0.7









- ▶ İlk kontrol 1 ay sonra (Nisan 2020)
- ▶ GK: 0.15/0.7
- ▶ Takiplerde solda görme bozuluyor.

- ▶ Temmuz 2020 GK: 0.2/ 0.2
- ▶ Temmuz 2020 sol göze suprakoroidal MKH yapıldı.

- ▶ AĖUSTOS 2020: GK: 0.2/0.3
- ▶ EKİM 2020: GK: 0.2/0.4
- ▶ 3 AYDA BİR TAKİPLERİ DEVAM EDİYOR


- ▶ SON MUAYENE EYLÜL 2021/SAĖ GÖZ POSTOP 18.AY
SOL GÖZ POSTOP 14.AY
- ▶ GK: 0.3/0.4 BİNOKULER 0.5 (PREOP GK: 0.05/0.2)




GK: 0.05 (11.2019)

SAĞ GÖZ


GK: 0.20 (08.2021)



GK: 0.7 (03.2020)









GK: 0.2(06.2020)



GK: 0.4 (08.2021)

SOL GÖZ

OCT VEGA



Suprachoroidal Adipose Tissue-Derived Mesenchymal Stem Cell Implantation in Patients with Dry-Type Age-Related Macular Degeneration and Stargardt's Macular Dystrophy: 6-Month Follow-Up Results of a Phase 2 Study

Ayşe Oner,¹ Zeynep Burcin Gonen,^{2,3} Duygu Gülmez Sevim,⁴
Neslihan Sinim Kahraman,⁴ and Metin Unlu, MD⁵

eISSN 2005-5447

International Journal of Stem Cells Published online October 31, 2020

<https://doi.org/10.15283/ijsc20025>

ORIGINAL ARTICLE

First Year Results of Suprachoroidal Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Degenerative Macular Diseases

Neslihan Sinim Kahraman¹, Zeynep Burcin Gonen², Duygu Gulmez Sevim³, Ayşe Oner¹

¹Ophthalmology Department, Kayseri Acibadem Hospital, Kayseri, Turkey

²Genome and Stem Cell Center, Kayseri, Turkey

³Ophthalmology Department, Erciyes University, Kayseri, Turkey

SONUÇ:

- ▶ SMD: ERGENLİK DÖNEMİNDE HIZLI GÖRME KAYBI YAPABİLİR.
- ▶ PEDIATRİK OLGULARDA MKH UYGULAMASINA ERİŞKİNLERDEN DAHA İYİ YANIT ALINABİLİR.